MétaCan
Menu
Back to cohort
Record W3154880036 · doi:10.1016/j.esmoop.2021.100117

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

2021· review· en· W3154880036 on OpenAlexaff
Bishal Gyawali, Elisabeth G.E. de Vries, Urania Dafni, Teresa Amaral, Jorge Barriuso, Jan Bogaerts, Antonio Calles, Giuseppe Curigliano, Carlos Gomez‐Roca, Barbara Kiesewetter, Sjoukje F. Oosting, Antonio Passaro, G. Pentheroudakis, Martine Piccart, Felipe Roitberg, Josep Tabernero, Noelia Tarazona, Dario Trapani, Ruth Wester, George Zarkavelis, Christoph Zielinski, Panagiota Zygoura, Nathan I. Cherny

Bibliographic record

VenueESMO Open · 2021
Typereview
Languageen
FieldEconomics, Econometrics and Finance
TopicEconomic and Financial Impacts of Cancer
Canadian institutionsQueen's University
FundersCilagFoundation MedicineChugai PharmaceuticalNovartis FarmacéuticaEuropean Society for Medical OncologyShireEisaiSeagenG1 TherapeuticsGenentechVeracyteSkylineDxRocheNordic NanovectorMeso Scale DiagnosticsLes Laboratories Pierre FabreCelldex TherapeuticsIpsenArray BioPharmaMerck KGaATaiho PharmaceuticalF. Hoffmann-La RocheAmgenBoehringer IngelheimRadius HealthDaiichi Sankyo EuropeServierBayerGilead SciencesNeraCareCancer Research UKWorld Health OrganizationSanofiNovartisAriad PharmaceuticalsPfizerAstraZenecaEli Lilly and CompanySamsungBristol-Myers Squibb
KeywordsMedicineClinical trialScale (ratio)Food and drug administrationAgency (philosophy)Clinical study designMedical physicsResearch designRisk analysis (engineering)PathologyStatistics

Abstract

fetched live from OpenAlex

BACKGROUND: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical benefit from cancer medicines reported in clinical trials. ESMO-MCBS scores assume valid research methodologies and quality trial implementation. Studies incorporating flawed design, implementation, or data analysis may generate outcomes that exaggerate true benefit and are not generalisable. Failure to either indicate or penalise studies with bias undermines the intention and diminishes the integrity of ESMO-MCBS scores. This review aimed to evaluate the adequacy of the ESMO-MCBS to address bias generated by flawed design, implementation, or data analysis and identify shortcomings in need of amendment. METHODS: As part of a refinement of the ESMO-MCBS, we reviewed trial design, implementation, and data analysis issues that could bias the results. For each issue of concern, we reviewed the ESMO-MCBS v1.1 approach against standards derived from Helsinki guidelines for ethical human research and guidelines from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, the Food and Drugs Administration, the European Medicines Agency, and European Network for Health Technology Assessment. RESULTS: Six design, two implementation, and two data analysis and interpretation issues were evaluated and in three, the ESMO-MCBS provided adequate protections. Seven shortcomings in the ability of the ESMO-MCBS to identify and address bias were identified. These related to (i) evaluation of the control arm, (ii) crossover issues, (iii) criteria for non-inferiority, (iv) substandard post-progression treatment, (v) post hoc subgroup findings based on biomarkers, (vi) informative censoring, and (vii) publication bias against quality-of-life data. CONCLUSION: Interpretation of the ESMO-MCBS scores requires critical appraisal of trials to understand caveats in trial design, implementation, and data analysis that may have biased results and conclusions. These will be addressed in future iterations of the ESMO-MCBS.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.734
metaresearch head score (Gemma)0.875
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesMetaresearch
DomainCandidate signal: Methods · Consensus signal: Methods
Study designCandidate signal: Systematic review · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.266
Threshold uncertainty score0.328

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.7340.875
Meta-epidemiology (narrow)0.0020.003
Meta-epidemiology (broad)0.0050.010
Bibliometrics0.0100.011
Science and technology studies0.0030.012
Scholarly communication0.0100.008
Open science0.0070.009
Research integrity0.0060.007
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.544
GPT teacher head0.537
Teacher spread0.007 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; the direct Gemma label and the distilled Codex classifier agree on what is shown here.

Study designSystematic review
DomainMethods
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations71
Published2021
Admission routes1
Has abstractyes

Explore more

Same venueESMO OpenSame topicEconomic and Financial Impacts of CancerFrench-language works237,207